6 recruiting. 6 Phase 1, 2 Phase 2.
By phase and status
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Trials (filtered) newest first · largest first
All 6 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)
BBT001, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Recruiting | 48 | 2026-06-29 | 2026-07-22 |
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
EDP-978, Placebo - Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | Phase 1 | Recruiting | 98 | 2026-04-01 | 2026-04-21 |
A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria
GTX-B001, Normal Saline - Healthy Subjects, Cold Urticaria | Phase 1 | Recruiting | 72 | 2025-10-06 | 2026-09-09 |
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
124I AT-01 - Cryopyrin-Associated Periodic Syndromes, Amyloidosis | Phase 1 | Recruiting | 30 | 2025-09-10 | 2026-05-19 |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants
Tacabrutideg, Placebo - Chronic Spontaneous Urticaria | Phase 1 | Recruiting | 58 | 2025-07-19 | 2026-09-09 |
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
Deucrictibant XR tablet, Placebo comparator to XR tablet, Deucrictibant 20 mg capsule - Hereditary Angioedema (HAE), Angioedema | Phase 1 / Phase 2 | Recruiting | 10 | 2025-03-10 | 2025-07-02 |
Narrower conditions
Chronic Urticaria (3) · Chronic Inducible Urticaria (2) · Amyloidosis (1) · Angioedema (1) · Angioedemas, Hereditary (1) · Cold Urticaria (1) · Cryopyrin-Associated Periodic Syndromes (1) · Familial dermographism (1) · Skin Diseases (1)
Broader conditions
Hypersensitivity (6) · Hypersensitivity, Immediate (6) · Immune System Diseases (6) · Skin Diseases, Vascular (6) · Skin and Connective Tissue Diseases (6) · Chronic Disease (5) · Disease Attributes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Skin Diseases (5) · Chronic Urticaria (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Cardiovascular Diseases (1)
Interventions
Saline Solution (1)
Sponsors
Bambusa Therapeutics (1) · BeOne Medicines (1) · Enanta Pharmaceuticals, Inc (1) · Granular Therapeutics Limited (1) · Institute for Asthma and Allergy (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Countries
United States (3) · China (2) · Germany (1)
Top investigators
Sara Alehashemi, M.D. (1)
NIH funding
2025 (1)